MARKER THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
MARKER THERAPEUTICS, INC. (MRKR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.20 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-18
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-09-30 was 40.00K shares.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-06-30 was 50.00K shares.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-03-31 was 1.32M shares.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-12-31 was 12.50K shares.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.20M shares.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 260.00K shares, a 35.77% increase from fiscal 2021.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 191.50K shares.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 147.50K shares, a 50.00% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | 1.20M shares 10-K · filed 2026-03-18 | |||||
| 2022-12-31 | 260.00K shares 10-K · filed 2023-03-22 | |||||
| 2021-12-31 | 191.50K shares 10-K · filed 2023-03-22 | 1.92M shares 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | 40.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 90.00K shares derived: sum of 2 quarters · filed 2020-11-09 | 1.41M shares 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | 50.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 1.37M shares 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | 1.32M shares 10-Q · filed 2020-05-11 | |||||
| 2016-12-31 | 12.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | 147.50K shares 10-K · filed 2017-03-14 | ||||
| 2016-09-30 | 135.00K shares 10-Q · filed 2016-11-04 | |||||
| 2015-12-31 | -86.44M shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-14 | -86.44M shares derived: sum of 2 quarters · filed 2017-03-14 | -61.80M shares derived: sum of 3 quarters · filed 2017-03-14 | 295.00K shares 10-K · filed 2017-03-14 | ||
| 2015-09-30 | 0.00 shares derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2016-04-14 | 24.64M shares derived: sum of 2 quarters · filed 2016-04-14 | 86.73M shares 10-Q/A · filed 2016-04-14 | |||
| 2015-06-30 | 24.64M shares derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2016-04-14 | 86.73M shares 10-Q/A · filed 2016-04-14 | ||||
| 2015-03-31 | 62.09M shares 10-Q/A · filed 2016-04-14 | |||||
| 2014-09-30 | 2.45M shares 10-Q · filed 2014-11-19 | |||||
| 2012-06-30 | 500.00K shares 10-Q/A · filed 2012-09-12 | |||||
| 2011-02-28 | 2.00M shares 10-Q/A · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |